Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Banner image

IP LitigationLife Sciences

Law360: Justices Struggle With BPCIA Enigma

April 28, 2017

IP LitigationLife Sciences

Law360: Justices Struggle With BPCIA Enigma

April 28, 2017

Back to Fish's Litigation Blog

 

In a recent article for Law360, Fish attorneys Tasha Francis and Jenny Shmuel discuss recent oral arguments for the Amgen Inc. v. Sandoz Inc. case, in which the U.S. Supreme Court has its first chance to weigh in on the Biologics Price Competition and Innovation Act (BPCIA).

To read the full article, visit Law360.


The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.

Related Tags

BPCIA
Amgen
Sandoz
Amgen v. Sandoz

Blog Authors

Headshot
Jenny Shmuel, Ph.D. | Associate

Dr. Jenny Shmuel represents clients on a range of intellectual property matters, with an emphasis on medical device and pharmaceutical technologies. She has extensive experience in pre-suit diligence, case management, expert and fact discovery, and brief writing, and has examined and...

Headshot
Tasha M. Francis, Ph.D. | Associate

Tasha Francis, Ph.D., practices intellectual property litigation with an emphasis on patent litigation. Her clients range from solo inventors and emerging companies in the biotechnology and biopharma industries to established international pharmaceutical companies. She has extensive...

Leave a Reply

Your email address will not be published. Required fields are marked *